Expert Guide: What Are the Steps in CAR T-Cell Therapy?
Summary: CAR T-cell therapy is an advanced, highly personalized cancer treatment that involves several carefully coordinated steps: eligibility assessment, T-cell collection, CAR T-cell manufacturing and expansion, lymphodepleting chemotherapy, CAR T-cell infusion, and post-infusion monitoring. In this guide, Dr. Yuelin He of the GoBroad Chunfu Institute of Hematology & Oncology explains what patients can expect and how to prepare at each stage, including the 3–4 hours typically needed for cell collection, the 2–4-week manufacturing period, the purpose of lymphodepleting chemotherapy, premedication before infusion, monitoring for cytokine release syndrome and other side effects, and the importance of regular follow-up after treatment.
Once you and your doctor have completed the necessary evaluation and decided that CAR T-cell therapy may be right for you, what does the treatment journey actually involve?
In general, CAR T-cell therapy involves six main steps: eligibility assessment → T-cell collection → CAR T-cell manufacturing and expansion → lymphodepleting chemotherapy → CAR T-cell infusion → monitoring and follow-up.
What do patients need to do during each step, and what should they keep in mind along the way?
1. Eligibility Assessment
The first step is to talk with your doctor about whether CAR T-cell therapy is an appropriate option for you.
Your doctor will review your overall health, test results, previous treatment history, and treatment goals, and will discuss the potential benefits and risks of CAR T-cell therapy with you. Together, you can decide whether to move forward.
2. T-Cell Collection
If you decide to proceed with CAR T-cell therapy, the next step is to collect your T cells.
This process, called leukapheresis, is similar in some ways to a blood donation. Blood is passed through an apheresis machine, which separates out the T lymphocytes needed for treatment, while the remaining blood components are returned to your body. The procedure usually takes about 3–4 hours. If your white blood cell count is low, your care team may recommend medication beforehand to help increase the number of cells available for collection.
3. CAR T-Cell Manufacturing and Expansion
The collected T cells are sent to a laboratory, where genetic engineering is used to add a chimeric antigen receptor (CAR)—essentially a “navigation system” that helps the cells recognize cancer cells. The modified cells are then expanded to produce a large number of CAR T cells. This manufacturing process usually takes about 2–4 weeks.
4. Lymphodepleting Chemotherapy (Preconditioning)
Before CAR T-cell infusion, patients receive lymphodepleting chemotherapy. This treatment reduces the body's existing lymphocytes and creates a more favorable environment for the infused CAR T cells to expand and work effectively. Lymphodepleting chemotherapy usually lasts about three days, followed by a rest period of around two to three days before CAR T-cell infusion.
If the tumor burden is high or the disease is progressing quickly, bridging therapy may also be needed before CAR T-cell infusion to help control the disease while the CAR T cells are being prepared.
5. CAR T-Cell Infusion
Before the infusion, the medical team will check and record your vital signs and may use cardiac monitoring as needed. About 30–60 minutes before the CAR T cells are given, you will also receive premedication to reduce the risk of allergic or infusion-related reactions.
The CAR T-cell infusion itself is usually straightforward. The cells are generally given through a vein using an infusion or transfusion set, and the process typically takes about 15–30 minutes. Afterward, the team will watch closely for symptoms such as fever, difficulty breathing, or rash, and will manage any discomfort promptly if it occurs.
6. Monitoring and Follow-Up
Once the infusion is complete, the CAR T cells can begin recognizing and attacking tumor cells.
Patients usually remain in the hospital for a period of close observation. The medical team will monitor for CAR T-related side effects, particularly cytokine release syndrome (CRS) and neurotoxicity, so that any problems can be identified and treated promptly.
At the same time, your doctors will use blood tests, imaging, and other assessments to evaluate whether the CAR T-cell therapy is working. An initial response assessment is commonly performed within the first month after infusion.
If the treatment is effective, regular follow-up remains essential. Follow-up helps monitor for disease recurrence and allows the care team to identify and manage any longer-term side effects related to CAR T-cell therapy.
From the Doctor
Compared with conventional drug treatment, CAR T-cell therapy involves a more complex treatment process. Staying in close communication with your care team throughout the journey is therefore very important and helps ensure that each stage of treatment is managed appropriately.